Tekmira Pharmaceuticals (TKMR) Coverage Initiated At Outperform By Leerink Partners

Analysts at Leerink Partners initiated coverage on Tekmira Pharmaceuticals Corporation (TKMR) with a ‘Outperform’ rating and a $25.00 price target in a research report issued to clients on Monday. Currently, only a couple of firms cover the stock of the Canadian-based company. Maxim Group has a ‘Buy’ rating and $23.00 price target on the equity, […] View the full post at: Tekmira Pharmaceuticals (TKMR) Coverage Initiated At Outperform By Leerink Partners Related posts: S&P Equity Research Boosts Operating Profit Target For Chevron